Vlad Schepkov
Vlad Schepkov - Activist investor reporter at StreetInsider.com/Investing.com. E-mail: [email protected]
View Older Stories View More Recent Stories
-
UPDATE: Cantor Fitzgerald Assumes SI-BONE Inc. (SIBN) at Overweight, "Encourage Investors to Acquire Shares at Current Attractive Valuation" (CORRECTION)
-
Arcutis Biotherapeutics Inc. (ARQT) PT Lowered to $57 at Mizuho Securities, Analyst Still Expects a "High Likelihood of a Positive Phase 3 Readout", Maintains Buy Rating
-
Mizuho Securities Reiterates Buy Rating, $20 Price Target on eFFECTOR Therapeutics (EFTR)
-
Truist Securities Reiterates BioXcel Therapeutics (BTAI) at Buy, $125 Price Target
-
Needham & Company Reiterates Genocea Biosciences (GNCA) at Buy, Expects "Any Signs of RECIST Clinical Activity... to Result in Significant Appreciation for GNCA"
-
Stifel Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA), Sees Stock Trading into Mid-$20s/sh If TIL Assay is Approved/De-risked
-
Cantor Fitzgerald Reiterates Fortress Biotech (FBIO) at Overweight, $6 PT, "Upward Earnings Estimate Revisions and Multiple Expansion will Drive FBIO's Stock Higher"
-
Cowen Reiterates Outperform Rating on Iovanace Biotherapeutics (IOVA)
-
BMO Capital Reiterates Outperform Rating on Merck (MRK), but Awaits "More Concrete Data" on Cardiovascular Programs
-
Collegium Pharmaceutical (COLL) PT Raised to $36 at Needham & Company on Updated Guidance, Immediate Synergies with BDSI
-
Merck's "Growth Growth Prospects in 2028+ are Underappreciate - Cantor Fitzgerald Reiterates Merck (MRK) at Overweight with $107 Price Target
-
"Current Valuation is Disconnected From Future Growth Outlook" - William Blair Reiterates Collegium Pharmaceutical (COLL) at Outperform
-
Dawson James Reiterates Buy Rating on ADiTx Therapeutics (ADTX)
-
Cowen Reiterates Outperform Rating on Twist Bioscience (TWST)
-
Oppenheimer Reiterates Outperform Rating on Clene (CLNN), Sees ALS Readout as Coming Next Quarter
-
H.C. Wainwright Reiterates Buy Rating, $21 Price Target on Alpine Immune Sciences (ALPN)
-
H.C. Wainwright Reiterates Buy Rating, $12 PT on CymaBay Therapeutic (CBAY)
-
"Buy The Weakness" - Oppenheimer Reiterates Alnylam (ALNY) at Outperform, Vutrisiran Delay is Minor, Continue to Expect Approval
-
Needham & Company Reiterates Buy Rating on Vaxcyte (PCVX)
-
Inozyme Pharma (INZY) Reiterated at Buy by Needham & Company with $23 Price Target, INZ-701 Data is Encouraging and "Near Best-Case"
-
Needham & Company Reiterates Buy Rating, $205 Price Target on Alnylam Pharmaceuticals (ALNY) Despite Delay of vutrisiran, "Still Have High Confidence vutrisiran Will be Approved"
-
Cantor Fitzgerald Reiterates Pacific Biosciences of California (PACB) at Overweight, $23 PT, Corteva Collaboration Further Demonstrates Power of PACB's Hifi Technology
-
Stifel Reiterates Buy Rating on WAVE Life Sciences (WVE), Believes "Caution is Warranted with WVE-004" Despite Favorably Looking Top-Line Data
-
Dawson James Reiterates Buy Rating, $7 PT on Athersys (ATHX), Continues to See Company as Undervalued
-
Stifel Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) Despite Vutrisiran NDA Delay
-
William Blair Reiterates Outperform Rating on Biohaven Pharmaceutical (BHVN), Sees Nurtec ODT as Leader in Migraine Therapies
-
Needham & Company Reiterates Acadia Pharmaceuticals (ACAD) at Hold Following AMX0035 Data, Notes It's Hard to Grasp Likelihood of Approval
-
Soleno Therapeutics Inc. (SLNO) PT Lowered to $3 at Oppenheimer, but Sees "Considerable Upside Potential" if DCCR is "Approvable"
-
H.C. Wainwright Reiterates Buy Rating, $69 Price Target on Cytokinetics (CYTK)
-
Agile Therapeutics (AGRX) PT Lowered to $1.50 at Oppenheimer
-
BMO Capital Reiterates Market Perform Rating on Amgen (AMGN)
-
Infinity Pharmaceutical (INFI) PT Slashed to $4 at Truist Securities, Continues to Sees Substantial Potential Upside but Cites Cash Overhang
-
Needham & Company Reiterates Zealand Pharma (ZEAL) at Buy with $42 PT, Views New Strategy and CEO Appointment Positively
-
Dawson James Reiterates Buy Rating on BioCardiAa (BCDA)
-
Ventyx Biosciences (VTYX) TYK2 Potentially "Best-in-Class", Company "Among the More Attractive" & "De-Risked" In Space - Jefferies Highly Bullish on VTYX Ahead of Phase 1 Readout, Reiterates BUY
-
H.C. Wainwright Reiterates Neutral Rating on AcelRx Pharmaceuticals (ACRX)
-
Cantor Fitzgerald Lowers PT to $5, Reiterates Overweight Rating on PAVmed (PAVM)
-
Needham & Company Reiterates Buy Rating, $20 PT on CorMedix (CRMD), Sees Latest Developments Removing Some Overhang
-
Tricida (TCDA) PT Lowered to $18 at Needham & Company
-
H.C. Wainwright Reiterates Buy Rating, $9 PT on BioCardiAa (BCDA)
-
Stifel Reiterates Buy Rating on Fulcrum Therapeutics (FULC)
-
Needham & Company Reiterates Buy Rating on I-Mab (IMAB)
-
William Blair Reiterates Outperform Rating on Kinnate Biopharma (KNTE), Sees Potential for Significant Upside in Shares
-
H.C. Wainwright Reiterates Buy Rating on Albireo Pharma (ALBO), "We Remain Highly Confident in Bylvay's Likelihood of Success"
-
Cantor Fitzgerald Reiterates Overweight Rating and $12 PT on Lucid Diagnostics (LUCD), "We Encourage Investors to Acquire LUCD Shares at Attractive Valuation"
-
Axsome Therapeutics (AXSM) PT Raised to $100 at Truist Securities on Sunosi Deal
-
Oppenheimer Reiterates CASI Pharmaceuticals (CASI) at Outperform, "CASI is an Underappreciated Story Among Small-cap Biotechs"
-
Needham & Company Reiterates Intra-Cellular Therapies (ITCI) at Buy with $65 PT, Sees Caplyta's Growth Accelerating & Potentially Beating Expectations
-
Mizuho Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)
-
Stifel Reiterates Buy Rating, $35 PT on Kinnate Biopharma (KNTE), "Remain Optimistic into KIN-2787 Monotherapy Data"
